From a pharmacological safety perspective, the adverse effect profile of retatrutide based on Phase 1 and Phase 2 clinical trial data (including the NEJM 2023 Phase 2 trial) includes: Gastrointestinal effects: Nausea, vomiting, diarrhoea, and constipation (the most commonly reported side effects in trial participants) Injection site reactions: Redness, swelling, or discomfort at the injection site Cardiovascular effects: Increases in heart rate have been observed in trial participants [21] [22] Hypoglycaemia: Particularly relevant in individuals with diabetes or those taking insulin, sulfonylureas, or other glucose-lowering agents Potential thyroid effects: GLP-1 receptor agonists have been associated with thyroid C-cell changes in rodent studies
J.FasmanG
Available in 10mg, 20mg, and 40mg lyophilized vials
Direct hypertrophy benefits of BPC-157 are not proven, and expectations for muscle size gains should remain conservative
3 Frontiers in Pharmacology (2024)NNMT as a candidate therapeutic target for metabolic syndrome (review)
Consult a qualified healthcare provider before beginning any peptide protocol or making changes to your care
